reboxetine has been researched along with Schizophrenia in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, SM; Ahsan, ZA; Cohn, T; Duncan, MJ; Faulkner, GEJ; Hahn, M; Lockwood, JT; Remington, G; Stogios, N; Takeuchi, H; Taylor, VH | 1 |
| Hu, X; Li, W; Pan, L | 1 |
| Horder, J; Matthews, PRL; Pearce, M | 1 |
| Amrami-Weizman, A; Fuchs, C; Gil-Ad, I; Kotler, M; Maayan, R; Pashinian, A; Poyurovsky, M | 1 |
| Hinkelmann, K; Jahn, H; Kellner, M; Raedler, TJ; Wiedemann, K; Yassouridis, A | 1 |
| Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J | 1 |
| Bellinghieri, PM; Bruno, A; De Fazio, P; Muscatello, MR; Pandolfo, G; Spina, E; Zoccali, R | 1 |
| Faragian, S; Fuchs, C; Pashinian, A; Poyurovsky, M | 1 |
| Artigas, F; Bortolozzi, A; Masana, M | 1 |
| Fuchs, C; Levi, A; Pashinian, A; Poyurovsky, M; Weizman, A; Weizman, R | 1 |
| Faragian, S; Fuchs, C; Isaacs, I; Poyurovsky, M; Schneidman, M; Weizman, A; Weizman, R | 1 |
| Arlt, J; Jahn, H; Kiefer, F; Naber, D; Raedler, TJ; Schick, M; Wiedemann, K | 1 |
| Faragian, S; Fuchs, C; Gil-Ad, I; Levi, A; Maayan, R; Pashinian, A; Poyurovsky, M | 1 |
| Helland, A; Spigset, O | 1 |
| Berk, M; Schutz, G | 1 |
3 review(s) available for reboxetine and Schizophrenia
| Article | Year |
|---|---|
Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Topics: Antipsychotic Agents; Betahistine; Famotidine; Fluoxetine; Humans; Melatonin; Metformin; Nausea; Nizatidine; Ranitidine; Reboxetine; Schizophrenia; Topiramate; Weight Gain | 2022 |
Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Norepinephrine; Reboxetine; Schizophrenia; Treatment Outcome | 2023 |
Selective noradrenaline reuptake inhibitors for schizophrenia.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Citalopram; Cognition; Humans; Morpholines; Quality of Life; Randomized Controlled Trials as Topic; Reboxetine; Schizophrenia; Serotonin and Noradrenaline Reuptake Inhibitors; Viloxazine | 2018 |
8 trial(s) available for reboxetine and Schizophrenia
| Article | Year |
|---|---|
The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Morpholines; Olanzapine; Reboxetine; Schizophrenia; Weight Gain; Young Adult | 2013 |
No effects of antidepressants on negative symptoms in schizophrenia.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Chi-Square Distribution; Citalopram; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Schizophrenia; Schizophrenic Psychology; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome | 2013 |
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Citalopram; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Olanzapine; Psychiatric Status Rating Scales; Reboxetine; Risperidone; Schizophrenia; Schizophrenic Psychology | 2014 |
Reboxetine adjuvant therapy in patients with schizophrenia showing a suboptimal response to clozapine: a 12-week, open-label, pilot study.
Topics: Adult; Antipsychotic Agents; Clozapine; Cognition Disorders; Drug Therapy, Combination; Female; Humans; Male; Morpholines; Pilot Projects; Reboxetine; Schizophrenia | 2014 |
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Benzodiazepines; Betahistine; Double-Blind Method; Female; Histamine Agonists; Humans; Male; Middle Aged; Morpholines; Olanzapine; Reboxetine; Schizophrenia; Treatment Outcome; Weight Gain; Young Adult | 2013 |
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Morpholines; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Reboxetine; Schizophrenia; Treatment Outcome; Weight Gain | 2003 |
Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Olanzapine; Reboxetine; Schizophrenia; Weight Gain | 2007 |
Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study.
Topics: Adult; Antidepressive Agents; Chronic Disease; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2001 |
4 other study(ies) available for reboxetine and Schizophrenia
| Article | Year |
|---|---|
Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Neuropsychological Tests; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Reboxetine; Schizophrenia; Schizophrenic Psychology; Young Adult | 2009 |
Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
Topics: Adrenergic Agents; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Electric Stimulation; Haloperidol; Idazoxan; Male; Microdialysis; Molecular Targeted Therapy; Morpholines; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Nucleus Accumbens; Prefrontal Cortex; Rats; Rats, Wistar; Reboxetine; Schizophrenia; Synaptic Transmission; Ventral Tegmental Area | 2011 |
Adjunctive use of reboxetine in schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Humans; Male; Morpholines; Norepinephrine; Reboxetine; Schizophrenia | 2004 |
Low serum concentrations of reboxetine in 2 patients treated with CYP3A4 inducers.
Topics: Adrenergic Uptake Inhibitors; Adult; Anticonvulsants; Bulimia Nervosa; Carbamazepine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Antagonism; Enzyme Induction; Female; Humans; Male; Middle Aged; Morpholines; Phenobarbital; Reboxetine; Schizophrenia | 2007 |